ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
CAPS Rating:
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
Recs
valuable patents strong balance sheet valuable partnerships with pharmacuetical companies capitalization low could be ripe for a buyout at double the current price